Effectiveness and safety of escitalopram treatment personalized based on therapeutic drug monitoring of drug plasma concentration: a prospective cohort study
Prospective cohort study shows TDM-guided dosing improves safety in outpatients with depression, suggesting potential benefits in treatment efficacy.
Key Points
Escitalopram treatment showed a 55% reduction in HAM-D scores by week eight, indicating significant improvement in depression symptoms.
The study involved 92 outpatients with baseline HAM-D scores above 13, highlighting the population targeted for treatment personalization.
Safety assessments revealed increased incidence of adverse drug reactions correlated with escitalopram plasma concentrations, stressing importance of monitoring.
TDM-guided dosing did not significantly improve effectiveness but increased treatment safety with no major adverse effects reported.